Natera (NASDAQ:NTRA – Get Free Report) and InnovAge (NASDAQ:INNV – Get Free Report) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, institutional ownership, dividends, analyst recommendations, risk and earnings.
Valuation & Earnings
This table compares Natera and InnovAge”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Natera | $2.31 billion | 16.26 | -$208.16 million | ($1.63) | -160.68 |
| InnovAge | $853.70 million | 1.72 | -$30.31 million | ($0.09) | -119.89 |
Analyst Recommendations
This is a summary of current ratings and target prices for Natera and InnovAge, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Natera | 1 | 4 | 14 | 3 | 2.86 |
| InnovAge | 2 | 1 | 0 | 0 | 1.33 |
Natera presently has a consensus target price of $259.22, suggesting a potential downside of 1.03%. InnovAge has a consensus target price of $7.00, suggesting a potential downside of 35.13%. Given Natera’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Natera is more favorable than InnovAge.
Risk & Volatility
Natera has a beta of 1.56, indicating that its stock price is 56% more volatile than the S&P 500. Comparatively, InnovAge has a beta of 0.45, indicating that its stock price is 55% less volatile than the S&P 500.
Insider & Institutional Ownership
99.9% of Natera shares are owned by institutional investors. Comparatively, 12.3% of InnovAge shares are owned by institutional investors. 5.1% of Natera shares are owned by company insiders. Comparatively, 1.0% of InnovAge shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares Natera and InnovAge’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Natera | -9.05% | -14.74% | -10.27% |
| InnovAge | -1.22% | -4.73% | -2.20% |
Summary
Natera beats InnovAge on 9 of the 15 factors compared between the two stocks.
About Natera
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.
About InnovAge
InnovAge Holding Corp. manages and provides a range of medical and ancillary services for seniors in need of care and support to live independently in its homes and communities. The company manages its business through Program of All-Inclusive Care for the Elderly (PACE) approach. It also offers in-home care services consisting of skilled, unskilled, and personal care; in-center services, such as primary care, physical therapy, occupational therapy, speech therapy, dental services, mental health and psychiatric services, meals, and activities; transportation to the PACE center and third-party medical appointments; and care management. The company serves participants in the United States; and operates PACE centers in Colorado, California, New Mexico, Pennsylvania, Florida, and Virginia. The company was formerly known as TCO Group Holdings, Inc. and changed its name to InnovAge Holding Corp. in January 2021. InnovAge Holding Corp. was founded in 2007 and is headquartered in Denver, Colorado.
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
